Tanya Taran

977 total citations
31 papers, 747 citations indexed

About

Tanya Taran is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Tanya Taran has authored 31 papers receiving a total of 747 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Tanya Taran's work include Advanced Breast Cancer Therapies (23 papers), Cancer Treatment and Pharmacology (17 papers) and Estrogen and related hormone effects (9 papers). Tanya Taran is often cited by papers focused on Advanced Breast Cancer Therapies (23 papers), Cancer Treatment and Pharmacology (17 papers) and Estrogen and related hormone effects (9 papers). Tanya Taran collaborates with scholars based in United States, France and Belgium. Tanya Taran's co-authors include David Miles, Pierfranco Conté, Valentina Guarneri, Christoph Thomssen, Laura Biganzoli, John A. Glaspy, Ian Smith, Nicholas J. Robert, Véronique Dièras and Xavier Pivot and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Tanya Taran

30 papers receiving 713 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tanya Taran United States	11	603	312	226	164	163	31	747
R. Goerner Germany	5	749 1.2×	224 0.7×	148 0.7×	118 0.7×	191 1.2×	8	884
F. Geurs Belgium	5	584 1.0×	81 0.3×	321 1.4×	158 1.0×	41 0.3×	11	687
Hiroyuki Yonou Japan	14	263 0.4×	185 0.6×	247 1.1×	20 0.1×	103 0.6×	27	547
R G Stillwell Australia	6	355 0.6×	103 0.3×	137 0.6×	38 0.2×	199 1.2×	7	549
Konstantinos Tsionos Greece	11	434 0.7×	56 0.2×	207 0.9×	189 1.2×	26 0.2×	22	630
Nancy S. Scher United States	6	276 0.5×	97 0.3×	95 0.4×	44 0.3×	42 0.3×	8	419
Vittorio Silingardi Italy	12	342 0.6×	99 0.3×	115 0.5×	13 0.1×	106 0.7×	28	619
Jakob Werner Hansen Denmark	13	264 0.4×	88 0.3×	216 1.0×	11 0.1×	153 0.9×	39	822
Furhan Yunus United States	10	374 0.6×	306 1.0×	148 0.7×	22 0.1×	104 0.6×	13	658
Maitrayee Goswami United States	16	165 0.3×	64 0.2×	191 0.8×	21 0.1×	57 0.3×	31	735

Countries citing papers authored by Tanya Taran

Since Specialization

Citations

This map shows the geographic impact of Tanya Taran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tanya Taran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tanya Taran more than expected).

Fields of papers citing papers by Tanya Taran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tanya Taran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tanya Taran. The network helps show where Tanya Taran may publish in the future.

Co-authorship network of co-authors of Tanya Taran

This figure shows the co-authorship network connecting the top 25 collaborators of Tanya Taran. A scholar is included among the top collaborators of Tanya Taran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tanya Taran. Tanya Taran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hortobágyi, G. N., Salomon M. Stemmer, H.A. Burris, et al.. (2021). LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2−) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). Annals of Oncology. 32. S1290–S1291. 41 indexed citations

Slamon, Dennis J., Patrick Neven, Stephen Chia, et al.. (2018). Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.. Journal of Clinical Oncology. 36(15_suppl). 1000–1000. 21 indexed citations

Jérusalem, Guy, Denise A. Yardley, Richard H. De Boer, et al.. (2018). Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study.. Journal of Clinical Oncology. 36(15_suppl). 1005–1005. 1 indexed citations

Slamon, Dennis J., Sara A. Hurvitz, David Chen, et al.. (2015). Predictive biomarkers of everolimus efficacy in HER2+ advanced breast cancer: Combined exploratory analysis from BOLERO-1 and BOLERO-3.. Journal of Clinical Oncology. 33(15_suppl). 512–512. 14 indexed citations

Rugo, Hope S., James C. Yao, Marianne Pavel, et al.. (2014). Stomatitis incidence and its relationship with efficacy: A meta-analysis of everolimus clinical studies.. Journal of Clinical Oncology. 32(26_suppl). 151–151. 1 indexed citations

Piccart, M., Hope S. Rugo, Mario Campone, et al.. (2013). Assessment of Genetic Alterations in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer from the BOLERO-2 Trial by Next-Generation Sequencing. Annals of Oncology. 24. iii25–iii25. 8 indexed citations

Hortobágyi, Gabriel N., Martine Piccart, Hope S. Rugo, et al.. (2013). Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). LBA509–LBA509. 59 indexed citations

Rugo, Hope S., Mario Campone, Michael Gnant, et al.. (2013). BOLERO-2: Efficacy and safety of first-line everolimus plus exemestane in advanced breast cancer.. Journal of Clinical Oncology. 31(26_suppl). 152–152. 5 indexed citations

Perez, Alejandra, Hope S. Rugo, José Baselga, et al.. (2013). Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). 558–558. 3 indexed citations

10.

Ejlertsen, Bent, Guy Jérusalem, Sara A. Hurvitz, et al.. (2013). BOLERO-6: Phase II study of everolimus plus exemestane versus everolimus or capecitabine monotherapy in HR⁺, HER2^- advanced breast cancer.. Journal of Clinical Oncology. 31(15_suppl). TPS660–TPS660. 7 indexed citations

11.

Piccart, Martine, Shinzaburo Noguchi, Kathleen I. Pritchard, et al.. (2012). Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology. 30(15_suppl). 559–559. 33 indexed citations

12.

Pritchard, Kathleen I., Howard A. Burris, Hope S. Rugo, et al.. (2012). Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2.. Journal of Clinical Oncology. 30(15_suppl). 551–551. 1 indexed citations

13.

Burris, H.A., J. Thaddeus Beck, Hope S. Rugo, et al.. (2012). Health-Related Quality of Life (QOL) in Metastatic Breast Cancer Patients Treated With Everolimus and Exemestane Versus Exemestane Monotherapy. Annals of Oncology. 23. ix121–ix122. 1 indexed citations

14.

Hart, Lowell L., José Baselga, Hope S. Rugo, et al.. (2012). Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets).. Journal of Clinical Oncology. 30(27_suppl). 102–102.

15.

Hurvitz, Sara A., Fabrice André, Howard A. Burris, et al.. (2012). BOLERO-1: A randomized, phase III, double-blind, placebo-controlled multicenter trial of everolimus in combination with trastuzumab and paclitaxel as first-line therapy in women with HER2-positive (HER2⁺), locally advanced or metastatic breast cancer (BC).. Journal of Clinical Oncology. 30(15_suppl). TPS648–TPS648. 12 indexed citations

16.

Arena, Francis P., Shinzaburo Noguchi, Kathleen I. Pritchard, et al.. (2012). Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial.. Journal of Clinical Oncology. 30(27_suppl). 99–99. 13 indexed citations

17.

Rugo, Hope S., Howard A. Burris, Michael Gnant, et al.. (2012). Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2.. Journal of Clinical Oncology. 30(27_suppl). 104–104. 2 indexed citations

18.

Guarneri, Valentina, David Miles, Nicholas J. Robert, et al.. (2010). Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Research and Treatment. 122(1). 181–188. 224 indexed citations

19.

Guarneri, Valentina, David Miles, Nadège Robert, et al.. (2009). Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials.. Cancer Research. 69(24_Supplement). 208–208. 1 indexed citations

20.

Miles, David, Gilles Romieu, Luc Dirix, et al.. (2008). Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO.. Journal of Clinical Oncology. 26(15_suppl). LBA1011–LBA1011. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact